Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.59 |
| ▸ | CTSS | P25774 | 9/20 | 0.57 |
| ▸ | CTSK | P43235 | 7/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 5/20 | 0.48 |
| ▸ | PPARG | P37231 | 4/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
| ▸ | ITGAV | P06756 | 1/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14250214 | 1.00 | ACE (0.59) | ACECTSSCTSKPTPN1ITGB3 | |
| SCHEMBL1202421 | 1.00 | ACE (0.59) | ACECTSSCTSKPTPN1ITGB3 | |
| SCHEMBL27153880 | 0.92 | ACE (0.55) | ACECTSSCTSKPTPN1ITGB3 | |
| SCHEMBL27152900 | 0.92 | ACE (0.55) | ACECTSSCTSKPTPN1ITGB3 | |
| SCHEMBL25186509 | 0.91 | ACE (0.54) | ACECTSSCTSKPTPN1ITGB3 | |
| SCHEMBL17580003 | 0.91 | ACE (0.54) | ACECTSSCTSKPTPN1ITGB3 | |
| SCHEMBL20551144 | 0.88 | CTSS (0.54) | ACECTSSCTSKPTPN1ITGB3 | |
| SCHEMBL20551147 | 0.88 | CTSS (0.54) | ACECTSSCTSKPTPN1ITGB3 | |
| SCHEMBL21643078 | 0.88 | CTSS (0.57) | ACECTSSCTSKPTPN1ITGB3 | |
| SCHEMBL21643081 | 0.88 | CTSS (0.57) | ACECTSSCTSKPTPN1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116444499-B | Phenylalanine derivative containing 4-quinazolinone and preparation method and application thereof | 山东大学 | 2024-09-06 | — | — | CN | claimed |
| CN-117658990-A | 4-quinazolinone derivative containing benzenesulfonamide piperazinone, and preparation method and application thereof | 山东大学 | 2024-03-08 | — | — | CN | claimed |
| CN-117384240-A | HIV-1 capsid protein degradation agent based on hydrophobic tag technology and preparation method and application thereof | 山东大学 | 2024-01-12 | — | — | CN | claimed |
| CN-116444499-A | Phenylalanine derivative containing 4-quinazolinone and preparation method and application thereof | 山东大学 | 2023-07-18 | — | — | CN | claimed |
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12630808-B2 | Modified archaeal family b polymerases | Singular Genomics Systems, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12594276-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2026-04-07 | — | — | US | disclosed |
| US-20260091017-A1 | TREATMENTS FOR INFLAMMATION | AUCKLAND UNISERVICES LTD (NZ) | 2026-04-02 | — | — | US | disclosed |
| US-20260085299-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12564644-B2 | Cyclodextrin complexes of specialized proresolving mediators | THETIS PHARMACEUTICALS LLC (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4677087-A1 | NOVEL TREATMENTS FOR OCULAR DISORDERS | Glaukos Corporation (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20030013881-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20030004360-A1 | Processes and intermediates for preparing benzyl epoxides | PHARMACIA & UPJOHN COMPANY | 2003-01-02 | — | — | US | disclosed |
| WO-2002100818-A2 | AMINEDIOLS AS AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002100820-A1 | SUBSTITUTED AMINOALCOHOLS USEFUL IN TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1265849-A2 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-21 | — | — | US | disclosed |
| US-20020019403-A1 | Methods to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2001070672-A2 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091017-A1 | TREATMENTS FOR INFLAMMATION | P2RX7, NLRP3, PYCARD | ACE 3545/4885CTSS 614/4885CTSK 583/4885 |
| US-12630808-B2 | Modified archaeal family b polymerases | SSU72, POLB, POLQ | ACE 1258/4885CTSS 3439/4885CTSK 3867/4885 |
| US-12594276-B2 | Inhibitors of human immunodeficiency virus replication | SAMHD1, IRF3, SLC34A1 | ACE 7/4885CTSS 70/4885CTSK 790/4885 |
| US-20030004360-A1 | Processes and intermediates for preparing benzyl epoxides | CYP2F1, VKORC1, VKORC1L1 | ACE 3720/4885CTSS 2132/4885CTSK 2148/4885 |
| US-20020019403-A1 | Methods to treat alzheimer's disease | PSEN1, PSEN2, BACE1 | ACE 181/4885CTSS 1957/4885CTSK 1577/4885 |
| US-20030013881-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, BACE1 | ACE 164/4885CTSS 2237/4885CTSK 1613/4885 |
| US-20260085299-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | POLB, POLM, POLRMT | ACE 565/4885CTSS 1137/4885CTSK 2422/4885 |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, BACE1 | ACE 269/4885CTSS 2221/4885CTSK 1785/4885 |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | DNMT3A, POLB, POLM | ACE 663/4885CTSS 2859/4885CTSK 3873/4885 |
| US-12564644-B2 | Cyclodextrin complexes of specialized proresolving mediators | ALOX15, ALOX12, PTGES | ACE 3413/4885CTSS 823/4885CTSK 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.